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Objectives: The ribosomal methylase Erm(41) confers inducible resistance to macrolides in Mycobacterium
abscessus. The aim of this work was to systematically study and compare drug susceptibility to clarithromycin
and azithromycin in M. abscessus and Mycobacterium chelonae clinical isolates with a particular focus on indu-
cible drug resistance.
Methods: Clinical isolates of M. abscessus subsp. abscessus (n¼21), M. abscessus subsp. bolletii (n¼16), M.
abscessus subsp. massiliense (n¼10) and M. chelonae (n¼22) were characterized regarding their erm(41) and
rrl genotypes and subjected to drug susceptibility testing (DST) for clarithromycin and azithromycin. Microdilution
DST was performed in cation-adjusted Mueller–Hinton broth (pH 7.4) with readings at days 3, 7 and 12 and with
pre-incubation at subinhibitory macrolide concentrations for erm(41) induction. In addition, the influence of var-
iations in pH and growth medium on DST results was examined.
Results: MICs of azithromycin were consistently higher than those of clarithromycin. In strains with an inducible
erm(41) gene, high median MICs of≥256 mg/L on day 12 were observed for both clarithromycin and azithromy-
cin. Inducible resistance was at least as pronounced for azithromycin as for clarithromycin.
Conclusions: Our findings do not support the suggestion of a preferential use of azithromycin over clarithromycin
in order to limit inducible macrolide resistance. Both compounds provoked a comparable resistance phenotype in
M. abscessus. Caution is needed when using either azithromycin or clarithromycin for treatment of M. abscessus
infections.
Keywords: macrolides, rapidly growing mycobacteria, inducible resistance, drug susceptibility testing
Introduction
Azithromycin is an orally administered azalide antimicrobial that
is structurally related to macrolides. The serum concentration of
azithromycin is lower than that of clarithromycin and erythromy-
cin,1 as azithromycin is rapidly removed from the circulation and
extensively distributed to intracellular compartments.1 – 3 These
unique pharmacokinetic properties of azithromycin allow for single
daily dosages and intermittent treatment,1 which can be beneficial
for patient compliance, especially in the context of long-term regi-
mens commonly required in mycobacterial infections.
Newer macrolides are considered key agents for the treatment
of emerging infections caused by the closely related, rapidly
growing mycobacterial species Mycobacterium abscessus and
Mycobacterium chelonae.4 In both species, acquired resistance
to macrolides occurs through point mutations at positions 2058
or 2059 of the 23S rRNA (rrl) gene.5,6 In contrast to M. chelonae,
M. abscessus harbours an inducible ribosomal methylase,
Erm(41), which represents an additional intrinsic resistance
mechanism against macrolides. Inducible resistance can be
demonstrated either by pre-incubation for 3 days prior to drug
susceptibility testing (DST) using subinhibitory macrolide concen-
trations between 0.125×and 0.5×MIC or by prolonging incubation
up to 12–14 days.5,7,8
The subspecies designations within M. abscessus sensu lato, i.e.
M. abscessus subsp. abscessus, M. abscessus subsp. bolletii and M.
abscessus subsp. massiliense, are the subject of an ongoing taxo-
nomic debate.5,9 – 13M. abscessus subsp. abscessus and M. absces-
sus subsp. bolletii both usually carry an inducible erm(41) gene.9
Recently, Bastian et al.9 reported that a single nucleotide
exchange, T28C (Trp-10Arg), in erm(41) leads to a loss of
methylase activity in M. abscessus subsp. abscessus, resulting in
a phenotype that is naturally susceptible to macrolides. M. absces-
sus subsp. massiliense differs from M. abscessus subsp. abscessus
and M. abscessus subsp. bolletii by an erm(41) that is dysfunc-
tional due to two characteristic deletions (bases 64 –65 and
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159–432).5,13 Interestingly, two strains of M. abscessus subsp.
massiliense with a functional erm(41) gene have been described
recently.14
Data comparing the efficacy of clarithromycin and azithromy-
cin in rapidly growing mycobacteria (RGM) are scarce. Using the
agar gradient diffusion method (Etest), Bastian et al.9 reported
that MICs of azithromycin for M. abscessus complex tend to be
higher than those of clarithromycin. This is in accordance with
an early report of Brown et al.,15 who observed higher MICs of
azithromycin compared with clarithromycin for M. abscessus
and M. chelonae using broth microdilution assays. However, the
procedures used for species identification in the latter study at
that time do not reflect current state-of-the-art taxonomy.15 In
contrast with these studies, Choi et al.16 more recently reported
that azithromycin is a weaker inducer of erm(41) gene expression
than clarithromycin and should therefore be preferred in antibiotic
therapy of M. abscessus infections. The aim of this work was to
systematically evaluate the in vitro drug susceptibility of clarithro-
mycin and azithromycin in M. abscessus and M. chelonae clinical
isolates, with emphasis on inducible resistance.
Materials and methods
Strains
Clinical isolates of M. abscessus subsp. abscessus (n¼21), M. abscessus
subsp. bolletii (n¼16),M. abscessus subsp.massiliense (n¼10) andM. che-
lonae (n¼22) were isolated from patient specimens between 2005 and
2013. Species identification was based on the sequences of the 16S
rRNA, the rpoB and the erm(41) genes as described previously.13,17,18
The erm(41) and rrl genotypes were determined by DNA sequence analysis
as described previously.19 In brief, the amplification primers used were
MCLR 19F (5′-GTAGCGAAATTCCTTGTCGG-3′, E. coli rrl positions 1930–
1949) and MCLR 21R (5′-TTCCCGCTTAGATGCTTTCAG-3′, E. coli rrl positions
2765 –2745) for the rrl gene and erm41f2 (5′-GACCGGGGCCTTCTT
CGTGAT-3′) and erm41r2 (5′-GACTTCCCCGCACCGATTCC-3′) for erm(41).
The PCR conditions for the rrl PCR were 3 min at 958C, followed by 30 cycles
at 958C for 60 s, 488C for 60 s and 728C for 120 s. The PCR conditions
for erm(41) were 5 min at 958C, followed by 40 cycles at 948C for 30 s,
558C for 30 s and 728C for 60 s. Sequencing was performed using
an Applied Biosystems 3130 Genetic Analyzer and BigDye Terminator
Cycle Sequencing chemistry (Applied Biosystems, Carlsbad, CA, USA).
The sequences were analysed using Lasergene SeqMan software
(DNASTAR, Madison, WI, USA), the SmartGene database (SmartGene
Zug, Switzerland) and the BLAST algorithm (http://blast.ncbi.nlm.nih.gov).
To identify mutations in rrl, sequences were compared with the published
M. abscessus subsp. abscessus genome (GenBank accession number
NC_010397.1). The published sequences of M. abscessus subsp. abscessus
strains ATCC 19977 (T28 sequevar, GenBank accession number
FJ358483.1) and CR5701 (C28 sequevar, GenBank accession number
HQ127366.1) were used as references for erm(41) analysis.
DST
DST was performed based on CLSI document M24-A2.20 Antimicrobial
compounds (Sigma–Aldrich, Buchs, Switzerland) were dissolved in DMSO
(clarithromycin) or ethanol (azithromycin), filter sterilized, aliquotted into
stock solutions of 5 g/L and stored at2808C. Working solutions (256 mg/L,
maximum final solvent concentration 5% v/v) were prepared by diluting
thawed aliquots of the respective stock solutions in cation-adjusted
Mueller–Hinton broth (CAMHB; Becton Dickinson, Allschwil, Switzerland)
at pH 7.4. Two-fold serial dilutions of the working solutions were prepared
in CAMHB using sterile 96-well microtitre plates (Greiner Bio-One, St Gallen,
Switzerland). Visible precipitates indicative of decreased solubility of azith-
romycin or clarithromycin were not observed. Drug-free solutions were
tested to exclude inhibitory activity of the solvents alone. For all antibiotics,
a growth control containing no antibiotic and a negative control contain-
ing only CAMHB were included. Mycobacterium peregrinum ATCC 700686
was used as a quality control (QC) strain to test each new lot of antibiotic
stock solutions. QC ranges were applied as recommended by the CLSI.20
In addition, M. abscessus ATCC 19977 was tested with each new lot of
antimicrobials as an internal QC.
For inoculum preparation, colonies were taken from fresh pure cultures
grown on Luria-Bertani (LB) agar using sterile cotton swabs and trans-
ferred into glass vials containing 2 mL of sterile saline. Bacterial suspen-
sions were adjusted to a turbidity equivalent to that of a ≥0.5 McFarland
standard and diluted in CAMHB to generate a final inoculum suspension of
1–5×105 cfu/mL. Each inoculum solution was checked for purity and
correct concentration by obtaining cfu counts of suitable dilutions plated
on LB agar. After inoculation, microdilution plates were covered with adhe-
sive seals and incubated at 378C for M. abscessus sensu lato or 308C for
M. chelonae. Growth was assessed by visual inspection of the microtitre
plates after 3, 7 and 12 days of incubation. In accordance with Nash
et al.,5 a clarithromycin MIC of.32 mg/L at day 12 was used as the criter-
ion for inducible macrolide resistance. For pre-incubation experiments, MIC
testing was repeated following 3 days of pre-incubation of liquid cultures
in 0.25×MIC of clarithromycin and azithromycin, respectively.5,7,8 Prior to
MIC testing, pre-incubated liquid cultures were pelleted and washed twice
using CAMHB to remove residual antibiotics. For all MIC determinations
using pre-incubated isolates, sequencing of the erm(41) gene was per-
formed before and after the 3 day pre-incubation period as well as at
day 12 of MIC testing in order to exclude the simultaneous presence of
mixed C28 and T28 populations or a potential selection of the T28
genotype.
Results
DST
Using the broth microdilution method based on the current CLSI
recommendations,20 we determined MIC ranges and median
MICs of clarithromycin and azithromycin for a set of clinical RGM
isolates: M. abscessus subsp. abscessus (T28 sequevars), n¼21;
M. abscessus subsp. bolletii, n¼16; M. abscessus subsp. massi-
liense, n¼10; and M. chelonae, n¼22 (Table 1). The data show
that the MICs of azithromycin were consistently higher than
those of clarithromycin for all examined isolates. In strains carry-
ing an inducible Erm(41) methylase, high median MICs of both
clarithromycin and azithromycin were observed at day 7 (azithro-
mycin .256 mg/L and clarithromycin 32 mg/L for M. abscessus
subsp. abscessus T28 sequevars; azithromycin .256 mg/L and
clarithromycin 128 mg/L for M. abscessus subsp. bolletii).
Assessment of inducible macrolide resistance
We additionally studied the effect of pre-incubation with macro-
lides on selected M. abscessus isolates. For M. abscessus subsp.
abscessus ATCC 19977 and a clinical M. abscessus subsp. absces-
sus isolate [both erm(41) T28 sequevars], pre-incubation at subin-
hibitory concentrations of either clarithromycin or azithromycin
resulted in a marked increase in the MICs of both compounds
between days 3 and 12 (Figure 1a and b). Inducible resistance
was at least as pronounced against azithromycin as against cla-
rithromycin in M. abscessus subsp. abscessus erm(41) T28 seque-
vars, regardless of pre-incubation (Figure 1a and b). A similar but
much less pronounced increase in MIC values was observed for
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the two M. abscessus subsp. abscessus erm(41) C28 sequevars,
again regardless of pre-incubation (Figure 1c and d).
Azithromycin and clarithromycin MIC readings on day 12 were
below or around 16 and 2 mg/L, respectively, and thus much
lower than those for the two T28 sequevars (both .256 mg/L,
Figure 1a and b). Interestingly, the day 12 azithromycin values
for the two C28 sequevars were clearly higher than the day 12
azithromycin MICs for clinical M. abscessus subsp. massiliense iso-
lates, which carry a large deletion in the erm(41) gene (see
Figure 1e). A control clinical M. abscessus subsp. abscessus isolate
carrying the rrl mutation A2058G showed clarithromycin and
azithromycin MICs of .256 mg/L already on day 3, regardless of
pre-incubation (Figure 1f).
Effect of the medium composition on the MICs of
clarithromycin and azithromycin
The two liquid media used for DST in the previous studies differ both
in their composition and acidity.9,16 Bastian et al.9 employed the
widely used CAMHB (pH 7.4) medium, which contains beef extract,
hydrolysed casein, starch and defined amounts of Ca2+ and Mg2+.
Choi et al.16 used Middlebrook 7H9 medium, which is a complex
liquid growth medium frequently used for the cultivation of myco-
bacteria. Middlebrook 7H9 has a lower pH (pH 6.8) and contains a
large number of inorganic salts. Since macrolide activity is sensitive
to pH,1,20 we hypothesized that the use of the different media may
influence the MIC values. Clarithromycin MICs for M. abscessus
subsp. abscessus ATCC 19977 on days 3, 7 and 12 were 4, 4 and
32 mg/L in Middlebrook 7H9 and 1, 8 and 256 mg/L in CAMHB,
respectively. For the same strain, the observed azithromycin MICs
were 8, 256 and .256 mg/L in Middlebrook 7H9 and 2, 64 and
256 mg/L in CAMHB, respectively. Azithromycin consistently
showed an inducible resistance phenotype comparable to that of
clarithromycin also at additional pH levels (pH 6.1 and 8.1) in
both media (data not shown).
Discussion
Macrolides such as clarithromycin and azithromycin are import-
ant components of therapeutic regimens against infections
caused by M. abscessus sensu lato and M. chelonae. Proper iden-
tification of M. abscessus isolates to the subspecies level is indis-
pensable, since significant differences exist in natural resistance
to macrolides due to a functional, dysfunctional or non-existent
erm(41) gene.5,9 Recently, Bastian et al.9 investigated a signifi-
cant number of M. abscessus complex clinical isolates by pheno-
typic DST for clarithromycin and azithromycin and by sequencing
of the erm(41) gene. These results indicated that MICs of azith-
romycin were generally higher than those of clarithromycin after
5 and 7 days of incubation.9 In contrast, experiments conducted
more recently by Choi et al.16 in M. abscessus subsp. abscessus
indicated that clarithromycin was a stronger inducer of
erm(41), leading to higher mRNA expression and a more rapid
increase in MICs during prolonged incubation compared with
azithromycin.
In order to resolve these apparently conflicting results, we
reanalysed the methodology used in the published studies and
conducted additional experiments. We have identified signifi-
cant methodological differences between the above-mentioned
studies and the current CLSI guideline, which recommends
broth microdilution in CAMHB for routine DST of RGM.20 Bastian
et al.9 used a commercial broth microdilution method (with
prolonged incubation for inducible macrolide resistance) for
clarithromycin and the agar gradient diffusion method (Etest)
for azithromycin to compare MIC ranges and mean MICs of the
two drugs. Choi et al.16 used pre-incubation and prolonged
incubation in Middlebrook 7H9 medium (pH 6.8) to evaluate
differences in inducible resistance between clarithromycin and
azithromycin.
Our data using CAMHB (pH 7.4) and test conditions based on
the CLSI guidelines show that the median MICs of azithromycin
for M. abscessus sensu lato and M. chelonae are markedly higher
Table 1. Clarithromycin and azithromycin DST results of M. abscessus complex and M. chelonae clinical isolates
Species/antibiotic
MIC range (mg/L) Median MIC (mg/L)
day 3 day 7 day 12 day 3 day 7 day 12
M. abscessus subsp. abscessus
clarithromycin (n¼21) ,0.5–8 ,0.5–256 32 to .256 0.5 32 256
azithromycin (n¼21) ,0.5–256 64 to .256 256 to .256 4 .256 .256
M. abscessus subsp. bolletii
clarithromycin (n¼16) 1–4 32–256 256 to .256 1 128 256
azithromycin (n¼16) 2–128 256 to .256 .256 32 .256 .256
M. abscessus subsp. massiliense
clarithromycin (n¼10) ,0.5 ,0.5–2 ,0.5–4 ,0.5 ,0.5 ,0.5
azithromycin (n¼10) 1–4 2–8 2–32 4 8 8
M. chelonae
clarithromycin (n¼22) ,0.5–1 ,0.5–2 ,0.5–4 ,0.5 ,0.5 1
azithromycin (n¼22) ,0.5–16 1–16 2–32 2 8 16
Shown are MICs for isolates with a wild-type rrl gene. M. abscessus subsp. abscessus and M. abscessus subsp. bolletii isolates carried an inducible Erm(41)
methylase (all T28 sequevars).
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than those of clarithromycin. Inducible resistance was compar-
able or even slightly more pronounced for azithromycin than for
clarithromycin in both M. abscessus subsp. abscessus erm(41)
T28 sequevars and M. abscessus subsp. bolletii (Table 1). We con-
ducted additional experiments with pre-incubation followed by
prolonged incubation using representative strains belonging to
the M. abscessus complex and compared the results with those
from our standard testing system (prolonged incubation alone).
In contrast to the recent report of Choi et al.,16 our results do
not show that clarithromycin triggers a more rapid or more pro-
nounced erm(41)-related macrolide resistance than azithromycin
in M. abscessus sensu lato. We observed a similar inducible resist-
ance phenotype for both compounds, despite the generally higher
MICs of azithromycin compared with clarithromycin (Table 1 and
Figure 1). We hypothesized that differences in growth media,
e.g. pH, might influence azithromycin activity, which might explain
the different results by Choi et al.16 However, additional experi-
ments in Middlebrook 7H9 and standard CAMHB medium ruled
out this possibility.
We also observed that M. abscessus subsp. abscessus erm(41)
C28 sequevars showed increasing MIC levels during prolonged
incubation with clarithromycin. This observation is supported by
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Figure 1. MICs of clarithromycin (CLR) and azithromycin (AZM) for M. abscessus complex isolates. (a) M. abscessus subsp. abscessus ATCC 19977,
erm(41): T28, rrl: wild-type. (b) M. abscessus subsp. abscessus clinical isolate, erm(41): T28, rrl: wild-type. (c and d) M. abscessus subsp. abscessus
clinical isolates, erm(41): C28, rrl: wild-type. (e) M. abscessus subsp. massiliense, erm(41): two deletions (2 and 276 bp), rrl: wild-type. (f) M.
abscessus subsp. abscessus clinical isolate, erm(41): T28, rrl: A2058G. For pre-incubation experiments, MIC testing was repeated following 3 days of
pre-incubation of liquid cultures in 0.25×MIC of clarithromycin and azithromycin, respectively.
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the previous finding that both T28 and C28 sequevars show a
comparable increase in mRNA transcripts upon exposure to
macrolides.5 The MICs of clarithromycin and azithromycin did
not increase to .32 mg/L at day 12 and thus were much lower
than those for M. abscessus subsp. abscessus T28 sequevars.
However, these MICs were clearly higher than the macrolide
MICs for M. abscessus subsp. massiliense, which possesses an
erm(41) with a large deletion (Table 1). These results suggest
that the single amino acid exchange, Trp-10Arg (T28C), does
not completely abort Erm(41) functionality and that a deletion
as found in M. abscessus subsp. massiliense is required to result
in a completely dysfunctional gene product. However, since only
two M. abscessus subsp. abscessus C28 sequevars were available
to us, this observation will require further clarification on a larger
set of such strains.
In conclusion, the median MICs of azithromycin were higher
and increased at a similar rate during prolonged incubation com-
pared with those of clarithromycin for clinical M. abscessus com-
plex isolates. Variation of our standard test conditions with
respect to pre-incubation, pH and medium did not support the
notion that azithromycin is a weaker inducer of erm(41)-related
macrolide resistance in M. abscessus sensu lato than clarithromy-
cin.16 Our data show that the single amino acid exchange
Trp-10Arg in erm(41) does not result in a complete loss of indu-
cibility, although MICs of both macrolides after prolonged incuba-
tion remained well below those for erm(41) T28 sequevars. Our
data further show that both clarithromycin and azithromycin
may trigger inducible macrolide resistance in vitro and that cau-
tion is advisable when using either compound in vivo in the pres-
ence of a functional Erm(41) methylase.
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